Study of tenecteplase into the artery after clot removal for stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tests a clot-dissolving drug called tenecteplase given directly into the artery after a mechanical thrombectomy (clot removal). The goal is to see if it helps improve blood flow to the small vessels in the brain after the main clot is removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are having a stroke caused by a blockage in a large artery in the front of the brain (confirmed by imaging).
- You are scheduled to have a procedure to remove the clot (mechanical thrombectomy).
- It has been less than 24 hours since your stroke began.
- You do not have a bleeding disorder, active internal bleeding, or recent use of blood thinners that would increase bleeding risk.
- You have not had a stroke or received a clot-busting drug in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a clot-busting drug called tenecteplase directly into the brain artery after a successful mechanical clot removal can improve recovery for people with a certain type of stroke. The goal is to see if it safely helps clear any remaining tiny clots and reduces disability.
This trial tests whether giving a clot-busting medication (tenecteplase) directly into the artery after an incomplete clot-removal procedure can improve blood flow and outcomes in people with large vessel strokes. It aims to help those who had partial reopening after mechanical thrombectomy.
This trial tests if giving a clot-busting drug (tenecteplase) directly into the brain artery after a successful clot-removal procedure can improve outcomes for people with a major stroke. It is for patients who had a large vessel blockage and received endovascular thrombectomy within 24 hours of symptoms starting.
This trial tests a clot-busting drug called tenecteplase given directly into the brain artery for people having a moderate stroke caused by a blockage in a medium-sized blood vessel. The goal is to see if it helps improve recovery when given within 24 hours of stroke symptoms starting.
This trial tests whether giving a clot-busting drug called tenecteplase directly into the blocked blood vessel in the brain can help people with a medium-sized vessel occlusion stroke. The drug may help restore blood flow and reduce disability, and it is given within 24 hours of symptom onset.
This trial tests whether a clot-dissolving drug called tenecteplase can improve recovery for people who had a large-vessel ischemic stroke 4.5 to 24 hours earlier and can’t have a mechanical clot removal procedure in time. If you join, you’ll get either tenecteplase or standard medical care, and the study will track your recovery and safety.
Hear when a new Acute Ischemic Stroke From Large Vessel Occlusion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.